Johnson & Johnson's most recent trend suggests a bullish bias. One trading opportunity on Johnson & Johnson is a Bull Put Spread using a strike $180.00 short put and a strike $175.00 long put offers a potential 16.01% return on risk over the next 22 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $180.00 by expiration. The full premium credit of $0.69 would be kept by the premium seller. The risk of $4.31 would be incurred if the stock dropped below the $175.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Johnson & Johnson is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Johnson & Johnson is bullish.
The RSI indicator is at 63.63 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Johnson & Johnson
Walgreens, drugmakers blame others for San Francisco's opioid crisis
Tue, 26 Apr 2022 22:41:03 +0000
Pharmacy chain Walgreens Boots Alliance and other defendants on Tuesday said they were not to blame for the opioid crisis in San Francisco, and that they acted responsibly when providing legal medications to patients in pain. “Almost all of those prescriptions were written by good, well-meaning doctors,” Walgreens attorney Kate Swift said during opening statements in a trial in San Francisco federal court. San Francisco has accused Walgreens, Teva Pharmaceutical Industries Ltd, AbbVie Inc's Allergan unit, and drug distributor Anda Inc, which is owned by Teva, of creating a “public nuisance” by flooding the city with prescription opioids and failing to prevent the drugs from being diverted for illegal use.
J&J sues to block sales of ‘dangerous' counterfeit HIV drugs
Tue, 26 Apr 2022 22:06:42 +0000
Johnson & Johnson has filed a lawsuit against drug distributors and a pharmacy seeking to stop the sale of counterfeit versions of its HIV drugs, months after a similar case brought by Gilead Sciences Inc. In a complaint filed April 7 and made public on Tuesday, J&J said it had learned of widespread counterfeiting through complaints from patients who received the wrong pills in their prescription bottle, and from the voluntary return of hundreds of bottles of counterfeit drugs from one of the defendants, distributor ProPharma Distribution LLC. The company also said that distribution of counterfeit versions of its HIV pills had come to light through Gilead's lawsuit https://www.reuters.com/article/gilead-sciences-hiv-idCNL4N2TY48H, filed in January.
Why High Dividend, Low Volatility ETFs are Beating the Market
Tue, 26 Apr 2022 20:19:08 +0000
These ETFs holds high quality, dividend paying stocks with low volatility
Drug/Biotech Stocks' Apr 27 Q1 Earnings Roster: GSK, AMGN & More
Tue, 26 Apr 2022 15:44:03 +0000
Let us take a look at four drug/biotech companies, namely, GSK, AMGN, ALKS and BMRN, which are due to release their quarterly results on Apr 27.
Is a Beat Likely for AbbVie (ABBV) This Earnings Season?
Tue, 26 Apr 2022 13:46:01 +0000
AbbVie's (ABBV) first-quarter results are expected to reflect the impact of strong demand for immunology drugs, aesthetics and cosmetics products. Investors are likely to focus on any update related to Humira LOE.
Also on Market Tamer…
Follow Us on Facebook